Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Patients with sinusitis, bronchitis, and uncomplicated urinary tract infections (UTIs) should receive fluoroquinolone antibacterial drugs only if other treatment options aren’t available, the FDA has advised.
In a Drug Safety Communication, the agency warned that systemic fluoroquinolones are associated with disabling and potentially permanent adverse effects involving tendons, muscles, nerves, and the central nervous system (http://1.usa.gov/1rIo90i).
Voelker R. New Fluoroquinolone Warning. JAMA. 2016;315(23):2514. doi:10.1001/jama.2016.7290
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: